Sumitomo Pharma (4506) Fundamentals 2026 — P/E 4.8x, Revenue Analysis | SniperIQ
Sumitomo Pharma (4506) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥576.9B, trading at ¥1286.00 on the JPX. This SniperIQ fundamentals page covers Sumitomo Pharma's valuation (P/E 4.8x, P/B 1.7x), profitability (net margin 23.6%), revenue (¥453.3B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sumitomo Pharma's market cap?
Sumitomo Pharma (4506) has a market capitalization of approximately ¥576.9B, trading at ¥1286.00 on the JPX. Market cap moves with the live share price.
What is Sumitomo Pharma's P/E ratio?
Sumitomo Pharma's trailing twelve-month P/E ratio is 4.8x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sumitomo Pharma?
Sumitomo Pharma runs a net profit margin of 23.6%, a gross margin of 56.7%, and an operating margin of 11.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sumitomo Pharma generate?
Sumitomo Pharma reported revenue of ¥453.3B for fiscal year 2026, with net income of ¥106.9B and earnings per share (EPS) of 268.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sumitomo Pharma pay a dividend?
Sumitomo Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sumitomo Pharma financially healthy?
Sumitomo Pharma carries a debt-to-equity ratio of 0.74x and a current ratio of 1.03x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sumitomo Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sumitomo Pharma (4506) the key facts are: market cap ¥576.9B, P/E 4.8x, revenue ¥453.3B, 52-week range 1050-3288. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sumitomo Pharma's full fundamentals live
Get Sumitomo Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.